View Categories

Mitral Valve Prolapse

11 min read

Background #

Mitral valve prolapse (MVP) is a valvular abnormality characterized by the systolic displacement of one or both mitral valve leaflets into the left atrium due to myxomatous degeneration or connective tissue abnormalities. This can lead to mitral regurgitation (MR) if leaflet coaptation is impaired. While often benign, MVP can be associated with arrhythmias, MR, and rarely sudden cardiac death. [1,2]

Classification or Types

By Etiology:

Primary (Sporadic or Genetic):

  • Associated with myxomatous degeneration; can be familial (autosomal dominant with variable expression) [3]

Secondary (Functional/Structural):

  • Occurs due to left ventricular remodeling (e.g., ischemic heart disease, hypertrophic cardiomyopathy)

By Leaflet Morphology (on echocardiography): [1]

Classic MVP: Leaflet thickness ≥5 mm with redundancy

Non-classic MVP: Leaflet thickness <5 mm

By MR Severity:

  • MVP with no MR
  • MVP with mild, moderate, or severe MR

Epidemiology

Sex: More common in women [1,4]

Age: Typically diagnosed in young to middle-aged adults; prevalence increases with age [4,5]

Prevalence: The estimated prevalence of MVP varies based on diagnostic criteria and study population. Using modern echocardiographic criteria, the prevalence is approximately 1.4% in the general population and 2.6% overall, with higher rates (8.7%) in hospital-based cohorts. [4] Population-based studies using rigorous diagnostic criteria have shown prevalence rates of 2.4% [1] to 2.6%, [4] substantially lower than earlier estimates of 5-15% which used less specific diagnostic criteria. [1,6] Among young adults, prevalence is estimated at 0.6-0.7%. [7,8]

Comorbidities: May coexist with connective tissue disorders (e.g., Marfan syndrome where 75% have MVP, Ehlers-Danlos syndrome), scoliosis, or chest wall deformities [3,6]

Pathophysiology

Mitral valve prolapse is fundamentally characterized by myxomatous degeneration of the mitral valve tissue, marked by progressive increases in the area and length of the valve leaflets. [3,9] The normal mitral valve consists of three distinct histological layers: the atrialis (a dense sheet of elastic fibers on the atrial side providing elasticity), the spongiosa (middle layer rich in glycosaminoglycans and proteoglycans within a spongy elastin network), and the fibrosa (ventricular side providing structural integrity). [3,9]

In MVP, myxomatous changes involve expansion of the spongiosa layer with accumulation of proteoglycans and disruption of the normal collagen architecture, leading to weakened leaflet structure. [3,10] This degenerative process results in thickened, redundant leaflets that prolapse superiorly into the left atrium beyond the mitral annulus during systole. [3,9] The pathophysiology involves an imbalance between synthesis and degradation of the extracellular matrix, with activated myofibroblasts expressing elevated levels of matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-13) and cysteine proteases (cathepsins S and K), leading to collagen and elastin fragmentation. [10,11]

Two main histological phenotypes are recognized: Barlow’s disease (diffuse myxomatous degeneration with thickened, redundant leaflets, severe annular enlargement, and elongated chordae, typically presenting in younger patients) and fibroelastic deficiency (more localized changes with chordal rupture, typically in older populations). [3,9,12]

The natural history spans decades, with progressive leaflet thickening and prolapse leading to mitral regurgitation. Chordal rupture is a frequent complication, arising from mechanical weakening combined with abnormal hemodynamic stresses from redundant leaflets. [3,9] In a subset of patients, MVP is associated with mitral annular disjunction (partial detachment of the mitral annulus from the ventricular myocardium), which creates mechanical stretch on the inferolateral left ventricular wall and papillary muscles, promoting myocardial fibrosis and creating a substrate for ventricular arrhythmias—the so-called “arrhythmogenic MVP syndrome.” [13,14,15]

Etiology #

Causes

  • Myxomatous degeneration of mitral valve leaflets and chordae
  • Connective tissue disorders (e.g., Marfan syndrome, Ehlers-Danlos syndrome)
  • Papillary muscle or chordal dysfunction
  • Idiopathic degeneration
  • Secondary to ischemic cardiomyopathy or hypertrophic cardiomyopathy

Risk Factors

  • Family history of MVP
  • Connective tissue disorders
  • Female sex
  • Low BMI or thin habitus
  • History of chest trauma (rare)
  • Mitral annular disjunction (associated with arrhythmic MVP)

Clinical Presentation #

History (Symptoms)

  • Often asymptomatic
  • Atypical chest pain (non-exertional, sharp or stabbing)
  • Palpitations or skipped beats
  • Fatigue or reduced exercise capacity
  • Dyspnea, especially if MR develops
  • Anxiety or panic attacks (possibly autonomic in origin)
  • Syncope or presyncope (rare, suggests arrhythmic MVP)

Physical Exam (Signs)

General Exam:

  • Patients typically appear well
  • May have features of connective tissue disorders (e.g., tall stature with long limbs in Marfan syndrome, joint hypermobility in Ehlers-Danlos)
  • May have skeletal abnormalities (pectus excavatum, scoliosis)

Vital Signs:

  • Usually normal; may have orthostatic changes in autonomic dysfunction

Cardiac Exam:

  • Midsystolic click followed by a late systolic murmur best heard at the apex
  • Click and murmur timing may vary with position:
    • Earlier with standing or Valsalva (decreased preload)
    • Later with squatting (increased preload)
  • Murmur may radiate to the axilla or base

Other findings:

  • Pectus excavatum or scoliosis in connective tissue disorders
  • Features of Marfan or Ehlers-Danlos in syndromic patients

Differential Diagnosis #

  • Mitral regurgitation (other causes)
  • Aortic stenosis or regurgitation
  • Hypertrophic cardiomyopathy
  • Tricuspid valve prolapse (rare)
  • Anxiety or panic disorder
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Pericarditis (if chest pain present)

Diagnostic Testing #

Initial Tests:

Transthoracic Echocardiogram (TTE):

  • Confirms leaflet prolapse >2 mm above annular plane in parasternal long-axis view
  • Assesses MR severity and leaflet thickness
  • Evaluates LV and LA size, systolic function
  • Assesses for mitral annular disjunction

Transesophageal Echocardiography (TEE):

  • Better resolution; used if TTE inconclusive or pre-surgery

Electrocardiogram (ECG):

  • Often normal
  • May show nonspecific ST-T changes or arrhythmias
  • In arrhythmic MVP: inferior T wave inversions (leads II, III, aVF), ST-segment depression

Holter Monitor or Event Recorder:

  • For palpitations or syncope
  • Detects supraventricular or ventricular arrhythmias

Additional Tests:

Cardiac MRI:

  • Useful for assessing myocardial fibrosis (late gadolinium enhancement)
  • Evaluates mitral annular disjunction
  • Identifies inferobasal and papillary muscle fibrosis in arrhythmic MVP
  • Quantifies mitral regurgitation

Exercise Stress Testing:

  • Assess exercise capacity
  • Evaluate for exercise-induced arrhythmias

Treatment #

I) Medical Management [16,17]

Asymptomatic MVP without MR:

  • No specific treatment
  • Reassurance and periodic monitoring

Symptomatic MVP (e.g., palpitations, chest pain):

  • Beta-blockers for palpitations or chest discomfort
  • Avoid stimulants (e.g., caffeine, decongestants)
  • Calcium channel blockers (e.g., verapamil) may be alternative

MVP with MR:

  • Follow mitral regurgitation guidelines per 2020 ACC/AHA recommendations
  • Diuretics and afterload reduction if heart failure develops
  • Anticoagulation for atrial fibrillation based on CHA2DS2-VASc score

Arrhythmic MVP:

  • Beta-blockers for ventricular ectopy
  • Consider ICD for secondary prevention after aborted SCD or sustained VT
  • ICD for primary prevention remains controversial; individualized based on high-risk features

II) Interventional/Surgical [16,17,18]

Indications for Mitral Valve Surgery (2020 ACC/AHA Guidelines): [16]

Class I Recommendations:

  • Symptomatic patients with chronic severe primary MR (regardless of LV function)
  • Asymptomatic patients with chronic severe primary MR AND:
    • LVEF ≤60%, OR
    • LV end-systolic dimension (LVESD) ≥40 mm

Class IIa Recommendations:

  • Asymptomatic patients with severe primary MR, LVEF >60%, and LVESD <40 mm, IF:
    • Likelihood of successful durable repair >95%
    • Expected surgical mortality <1%
    • Performed at a Primary or Comprehensive Valve Center

Class IIb Recommendations:

  • Asymptomatic patients with severe primary MR and normal LV function BUT progressive LV enlargement or decreasing LVEF on serial imaging

Surgical Options:

  • Mitral valve repair (strongly preferred over replacement for degenerative disease) [16,17]
  • Mitral valve replacement (if repair not feasible)

Transcatheter Options: [16,17]

  • Transcatheter edge-to-edge repair (TEER, e.g., MitraClip) for patients with:
    • High or prohibitive surgical risk
    • Favorable valve anatomy
    • Life expectancy ≥1 year
    • (Class IIa recommendation)

Consults #

Cardiology:

  • All patients with moderate to severe MR, arrhythmias, or progressive symptoms

Electrophysiology:

  • If ventricular arrhythmias, syncope, or features of arrhythmic MVP
  • For risk stratification of sudden death risk

Cardiothoracic Surgery:

  • For consideration of mitral valve repair/replacement when indicated

Genetic counseling:

  • If syndromic features or family history of connective tissue disease

Patient Education, Counseling, Screening, and Vaccines #

Patient Education:

  • Reassurance in benign MVP
  • Educate on warning symptoms: worsening dyspnea, palpitations, syncope
  • Avoid stimulants and maintain good hydration
  • Maintain regular exercise (unless symptomatic MR present)

Screening Recommendations:

The U.S. Preventive Services Task Force (USPSTF) does not recommend routine ECG screening for cardiovascular disease risk assessment in asymptomatic adults, including those with MVP. [19] The USPSTF recommends against screening with resting or exercise ECG to prevent cardiovascular disease events in asymptomatic adults at low risk (Grade D recommendation) and concludes that evidence is insufficient for intermediate or high-risk adults (I statement). [19]

For general cardiovascular health, the USPSTF recommends screening for high blood pressure and use of statins based on cardiovascular risk assessment. [20] The USPSTF also recommends behavioral counseling interventions to promote a healthful diet and physical activity. [21]

Vaccines: [22]

For adults with MVP, standard vaccination recommendations apply as established by the Advisory Committee on Immunization Practices (ACIP). The USPSTF defers to ACIP for specific immunization recommendations. [22] General recommendations include:

  • Annual influenza vaccine
  • Pneumococcal vaccination (PCV followed by PPSV23) for adults ≥65 years
  • COVID-19 vaccine per current ACIP guidelines
  • Routine adult vaccines (Tdap, etc.) as recommended

Endocarditis prophylaxis: [16]

Per 2020 ACC/AHA guidelines, endocarditis prophylaxis is NOT routinely recommended for isolated MVP. Exceptions include:

  • Prior history of infective endocarditis
  • Post surgical or transcatheter mitral valve repair or replacement

Follow-Up #

Echocardiogram:

  • Every 3–5 years in mild MVP without MR
  • Annually or every 6–12 months if moderate to severe MR present
  • More frequent if LV dilation or declining function

Holter monitor:

  • If symptoms suggest arrhythmia

Clinical Monitoring:

  • Monitor for development or progression of MR
  • Serial assessment of LV size and function
  • Lifestyle counseling and reinforcement of red flags
  • Adjust surveillance based on presence of arrhythmias, mitral annular disjunction, or LV dysfunction

References #

  1. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. doi:10.1056/NEJM199907013410101
  2. Nishimura RA, McGoon MD, Shub C, et al. Echocardiographically documented mitral-valve prolapse: long-term follow-up of 237 patients. N Engl J Med. 1985;313(21):1305-1309. doi:10.1056/NEJM198511213132101
  3. Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation. 2014;129(21):2158-2170. doi:10.1161/CIRCULATIONAHA.113.006702
  4. Offen S, Playford D, Strange G, et al. Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2025;11(5):631-642. doi:10.1093/ehjqcco/qcae060
  5. Delling FN, Rong J, Larson MG, et al. Evolution of mitral valve prolapse: insights from the Framingham Heart Study. Circulation. 2016;133(17):1688-1695. doi:10.1161/CIRCULATIONAHA.115.020621
  6. Levine RA, Triulzi MO, Harrigan P, Weyman AE. The relationship of mitral annular shape to the diagnosis of mitral valve prolapse. Circulation. 1987;75(4):756-767. doi:10.1161/01.CIR.75.4.756
  7. Flack JM, Kvasnicka J, Gardin JM, et al. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J. 1999;138(3 Pt 1):486-492. doi:10.1016/s0002-8703(99)70151-3
  8. Moustafa S, Mookadam F, Cooper L, et al. Prevalence of mitral valve prolapse and associated valvular regurgitations in healthy teenagers undergoing screening echocardiography. Paediatr Child Health. 2010;15(6):e24-e28. doi:10.1093/pch/15.6.e24
  9. Rabkin E, Aikawa M, Stone JR, et al. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104(21):2525-2532. doi:10.1161/hc4601.099489
  10. Tamura K, Fukuda Y, Ishizaki M, et al. Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. Am Heart J. 1995;129(6):1149-1158. doi:10.1016/0002-8703(95)90397-6
  11. Loardi C, Alamanni F, Trezzi M, et al. Biology of mitral valve prolapse: the harvest is big, but the workers are few. Int J Cardiol. 2011;151(2):129-135. doi:10.1016/j.ijcard.2010.11.004
  12. Anyanwu AC, Adams DH. Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency. Semin Thorac Cardiovasc Surg. 2007;19(2):90-96. doi:10.1053/j.semtcvs.2007.04.002
  13. Basso C, Perazzolo Marra M, Rizzo S, et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation. 2015;132(7):556-566. doi:10.1161/CIRCULATIONAHA.115.016291
  14. Essayagh B, Sabbag A, Antoine C, et al. Presentation and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol. 2020;76(6):637-649. doi:10.1016/j.jacc.2020.06.029
  15. Cameron JN, Kadhim KI, Kamsani SH, et al. Arrhythmogenic mitral valve prolapse: can we risk stratify and prevent sudden cardiac death? Arrhythm Electrophysiol Rev. 2024;13:e11. doi:10.15420/aer.2023.26
  16. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923
  17. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371. doi:10.1016/j.echo.2017.01.007
  18. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307-2318. doi:10.1056/NEJMoa1806640
  19. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cardiovascular disease risk with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(22):2308-2314. doi:10.1001/jama.2018.6848
  20. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(8):746-753. doi:10.1001/jama.2022.13044
  21. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(4):367-374. doi:10.1001/jama.2022.10951
  22. US Preventive Services Task Force. Immunizations for adults. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/immunizations-for-adults (Accessed November 2025). [Note: USPSTF defers to CDC Advisory Committee on Immunization Practices (ACIP) for specific vaccine recommendations. See https://www.cdc.gov/vaccines/schedules/index.html]
Updated on November 25, 2025